LV-320 NEW
| Price | $1430 | $1860 | $2675 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-28 |
Product Details
| Product Name: LV-320 | CAS No.: 2449093-46-1 |
| Supply Ability: 10g | Release date: 2025/10/28 |
Product Introduction
Bioactivity
| Name | LV-320 |
| Description | LV-320 is a potent, uncompetitive ATG4B inhibitor with an IC50 of 24.5 μM and a Kd of 16 μM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic, and active in vivo. These findings suggest that LV-320 will serve as a relevant chemical tool to study the various roles of ATG4B in cancer and other contexts [1]. |
| In vitro | LV-320 (0-120 μM; SKBR3, MCF7, JIMT1, and MDA-MB-231 cells) treatment leads to a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines [1]. LV-320 (120 μM; 48 hours; MDA-MB-231 cells) treatment results in an increase in LC3B-II, indicating that LV-320 blocks autophagic flux [1]. Western Blot Analysis [1] Cell Line: SKBR3, MCF7, JIMT1, and MDA-MB-231 cells Concentration: 0 μM, 25 μM, 50 μM, 75 μM, 100 μM, or 120 μM Incubation Time: Result: Resulted in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. Cell Autophagy Assay [1] Cell Line: MDA-MB-231 cells Concentration: 120 μM Incubation Time: 48 hours Result: Blocked autophagic flux. |
| In vivo | Administering LV-320 (100-200 mg/kg; oral gavage; three times over two days; GFP-LC3 mice) resulted in terminal blood and liver concentrations of 169 μM and 104 μM, respectively. This treatment significantly increased the accumulation of GFP-LC3 puncta and elevated LC3B-II protein levels in treated animals compared to controls, without causing notable toxicity at either dose [1]. The study utilized female GFP-LC3 mice aged 9-14 weeks [1], exploring the pharmacokinetics and the biological impact of LV-320 on autophagy-related markers. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 135 mg/mL (259.56 mM), Sonication is recommended. |
| Keywords | LV-320 | LV320 | LV 320 | CysteineProtease | Cysteine Protease | ATG4B |
| Inhibitors Related | Stavudine | Aceglutamide | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Curcumin | Valproic Acid | Paeonol | Naringin | Alginic acid | Gefitinib |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3310.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $30.00/2mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-12-05 | |
| $1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2022-07-14 | |
| $2675.00/100mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-03 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY